
USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$7.49B
Market Cap
63.48
P/E Ratio
1.12
EPS
$117.33
52 Week High
$49.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $664M |
| Total Revenue | $675M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | $137M |
| Selling General And Administrative | $280M |
| Research And Development | $247M |
| Operating Expenses | $527M |
| Investment Income Net | - |
| Net Interest Income | $25M |
| Interest Income | $25M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | $161M |
| Income Tax Expense | $20M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $141M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $137M |
| Ebitda | $137M |
| Net Income | $140M |
| Field | Value (USD) |
|---|---|
| Total Assets | $841M |
| Total Current Assets | $472M |
| Cash And Cash Equivalents At Carrying Value | $128M |
| Cash And Short Term Investments | $128M |
| Inventory | $12M |
| Current Net Receivables | $54M |
| Total Non Current Assets | $369M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $220M |
| Short Term Investments | $256M |
| Other Current Assets | $22M |
| Other Non Current Assets | - |
| Total Liabilities | $161M |
| Total Current Liabilities | $141M |
| Current Accounts Payable | $15M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $829K |
| Total Non Current Liabilities | $20M |
| Capital Lease Obligations | $6.9M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $6.9M |
| Other Current Liabilities | $124M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $680M |
| Treasury Stock | - |
| Retained Earnings | $544M |
| Common Stock | $136K |
| Common Stock Shares Outstanding | $113M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $198M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.3M |
| Capital Expenditures | $2.2M |
| Change In Receivables | - |
| Change In Inventory | $305K |
| Profit Loss | - |
| Cashflow From Investment | -$178M |
| Cashflow From Financing | -$28M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$16M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $141M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $664M |
| Total Revenue | $675M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | $137M |
| Selling General And Administrative | $280M |
| Research And Development | $247M |
| Operating Expenses | $527M |
| Investment Income Net | - |
| Net Interest Income | $25M |
| Interest Income | $25M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | $161M |
| Income Tax Expense | $20M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $141M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $137M |
| Ebitda | $137M |
| Net Income | $140M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Corcept Therapeutics Incorporated is a biopharmaceutical company headquartered in Menlo Park, California, that specializes in the discovery and development of therapies targeting severe metabolic, psychiatric, and oncological disorders. Employing a proprietary approach to cortisol modulation, Corcept aims to address significant unmet medical needs and enhance patient outcomes. With a promising pipeline of product candidates, the company is poised to deliver innovative solutions that not only improve patient quality of life but also generate value for its shareholders.